SCHEMBL3785147

SCHEMBL3785147

COc1ccc(Nc2nc(-c3cc(F)cc(C(N)=O)c3)cn3ccnc23)cc1OC

nearest known ligand 0.79

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 0.79
CD63 P08962 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3787170 0.90 SYK (0.80) SYKCD63
SCHEMBL4317859 0.88 SYK (1.00) SYKCD63
SCHEMBL4322904 0.88 SYK (1.00) SYKCD63
SCHEMBL3800520 0.87 SYK (0.73) SYK
SCHEMBL3809214 0.87 SYK (0.80) SYKCD63
SCHEMBL3805291 0.86 SYK (1.00) SYKCD63
SCHEMBL3795139 0.86 SYK (1.00) SYKCD63
SCHEMBL3791262 0.85 SYK (1.00) SYKCD63
SCHEMBL3794638 0.85 SYK (1.00) SYKCD63
SCHEMBL3788228 0.84 SYK (0.82) SYKCD63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252617-A1 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2010-11-24 EP claimed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US claimed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO claimed
US-8697699-B2 Imidazopyrazine SYK inhibitors GILEAD CONNECTICUT, INC. (US) 2014-04-15 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF GILEAD CONNECTICUT, INC. (US) 2013-01-24 US disclosed
EP-2252617-A1 6-ARYL-IMIDAZ0[L, 2-A]PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI Pharmaceuticals, Inc. (US) 2010-11-24 EP disclosed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US disclosed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US disclosed
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF Kronos Bio, Inc. 2009-09-03 US disclosed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed
WO-2009102468-A1 6-ARYL-IMIDAZ0[L, 2-A] PYRAZINE DERIVATIVES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023499-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF SYK, MYD88, BTK SYK 1/4885CD63 2609/4885
US-20090221612-A1 CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF SYK, MYD88, BTK SYK 1/4885CD63 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.